Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.54M | 14.86M | 18.56M | 18.67M | 19.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.57M | 25.95M | 28.93M | 29.03M | 29.40M |
| Operating Income | -24.57M | -25.95M | -28.93M | -29.03M | -29.40M |
| Income Before Tax | -24.22M | -24.89M | -26.99M | -25.77M | -26.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.22 | -24.89 | -26.99 | -25.77 | -26.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.22M | -24.89M | -26.99M | -25.77M | -26.80M |
| EBIT | -24.57M | -25.95M | -28.93M | -29.03M | -29.40M |
| EBITDA | -24.55M | -25.91M | -28.74M | -28.81M | -29.13M |
| EPS Basic | -0.28 | -0.30 | -0.35 | -0.35 | -0.38 |
| Normalized Basic EPS | -0.18 | -0.19 | -0.22 | -0.22 | -0.24 |
| EPS Diluted | -0.28 | -0.30 | -0.35 | -0.35 | -0.38 |
| Normalized Diluted EPS | -0.18 | -0.19 | -0.22 | -0.22 | -0.24 |
| Average Basic Shares Outstanding | 347.93M | 330.40M | 315.51M | 301.61M | 286.26M |
| Average Diluted Shares Outstanding | 347.93M | 330.40M | 315.51M | 301.61M | 286.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |